Ananda Pharma PLC - Ananda Hits Key Phase 1 Milestone for MRX1 CBD

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU, WHICH IS PART OF UNITED KINGDOM DOMESTIC LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

6 October 2025

ANANDA PHARMA PLC 

("Ananda" or the "Company") 

Ananda Pharma Hits Key Phase 1 Milestone for MRX1 CBD

President Trump Highlights Benefits of CBD for Chronic Pain

Ananda Pharma plc (AQSE: ANA, OTC: ANANF), a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions including endometriosis and chemotherapy induced peripheral neuropathy (CIPN), is pleased to announce a key milestone in its drug development programme. That the dosing phase of the Phase 1 pharmacokinetic (PK) is now complete.

Highlights

·    The last participant has received their final MRX1 dose in the PK study

·    This marks the Last Participant, Last Dose (LPLD) milestone in the Phase 1 healthy volunteer pharmacokinetic, safety and tolerability (PK) study at the clinical site in Melbourne, Australia

·    The database will now be locked and final readouts are on track for delivery in Quarter 1 2026

·    To view the supporting video and ask questions, please visit: https://investors.anandapharma.co.uk/link/eW315e.

The PK study enrolled  19 healthy adult volunteers (9 male and 10 female) across two dosing cohorts and was designed to characterise the pharmacokinetics, safety, tolerability, and food effect of MRX1 in humans. For more information on the study design, see the trial's clinicaltrials.gov page.

With dosing complete, the Company will now lock the database and the trial team will commence data analysis to determine the pharmacokinetic outcomes of the trial. The Company expects to be in a position to report on safety and tolerability in Q4 2025, with the first draft clinical trial report expected in Q1 2026 and final report shortly thereafter.

The data from this trial will be used for Federal Drug Administration ('FDA') regulatory filings and to help inform future trial protocols.

Ananda's Chief Executive Officer, Melissa Sturgess, commented: "Reaching Last Participant, Last Dose is an important milestone in our MRX1 development program. I am particularly pleased that half the participants in the study were female. It is crucial for our strategy to advance MRX1 CBD through the regulatory pathway for the treatment of pain associated with endometriosis that we understand how MRX1 CBD acts in the female body.

"With increasing attention on the role of CBD in elder care and chronic pain, highlighted most recently by President Trump's video post on Truth Social (https://truthsocial.com/@realDonaldTrump/posts/115283887618990920), we are encouraged that the dialogue around FDA approved pharmaceutical CBD is gaining prominence. We look forward to proceeding with data review and topline PK and safety analysis, with results expected in Q1 2026."

About Ananda Pharma

Ananda Pharma (AQSE:ANA, OTC:ANANF) is a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, including endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR).  The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh.

For more information, please visit our website:

To stay up to date with Ananda's news please follow our social media channels:  

·              Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93

·              Instagram: https://www.instagram.com/anandapharmaplc/

·              LinkedIn:  https://www.linkedin.com/company/anandapharma

·              X: https://twitter.com/AnandaPlc

·              Investor Meet Company: https://www.investormeetcompany.com/ananda-pharma-plc/register-investor

-Ends-

For the purposes of UK MAR, the Directors of the Company accept responsibility for the contents of this announcement.